M
Marguerite Koutsoukos
Researcher at GlaxoSmithKline
Publications - 50
Citations - 3115
Marguerite Koutsoukos is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Adjuvant. The author has an hindex of 20, co-authored 40 publications receiving 2565 citations.
Papers
More filters
Journal ArticleDOI
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Ming Li,Feng Gao,John R. Mascola,Leonidas Stamatatos,Victoria R. Polonis,Marguerite Koutsoukos,Gerald Voss,Paul A. Goepfert,Peter B. Gilbert,Kelli Greene,Miroslawa Bilska,Denise Kothe,Jesus F. Salazar-Gonzalez,Xiping Wei,Julie M. Decker,Beatrice H. Hahn,David C. Montefiori +16 more
TL;DR: There is an urgent need to establish standard panels of HIV-1 reference strains for wide distribution and a lack of uniformity in target strains used by different investigators to assess cross-neutralization has made the comparison of vaccine-induced antibody responses difficult.
Journal ArticleDOI
Protective Efficacy of Adenovirus/Protein Vaccines Against SIV Challenges in Rhesus Monkeys
Dan H. Barouch,Dan H. Barouch,Galit Alter,Thomas Broge,Caitlyn Linde,Margaret E. Ackerman,Eric P. Brown,Erica N. Borducchi,Kaitlin M. Smith,Joseph P. Nkolola,Jinyan Liu,Jennifer L. Shields,Lily Parenteau,James B. Whitney,Peter Abbink,David Ng’ang’a,Michael S. Seaman,Christy L. Lavine,James R. Perry,Wenjun Li,Arnaud D. Colantonio,Mark G. Lewis,Bing Chen,Holger Wenschuh,Ulf Reimer,Michael Piatak,Jeffrey D. Lifson,Scott A. Handley,Herbert W. Virgin,Marguerite Koutsoukos,Clarisse Lorin,Gerald Voss,Mo Weijtens,Maria G. Pau,Hanneke Schuitemaker +34 more
TL;DR: Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 Env, Gag, and Pol and boosted with AS01B-adjuvanted Sivmac32H Env gp140 demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIVmac251 challenges that infected all controls.
Journal ArticleDOI
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Pierre Vandepapelière,Yves Horsmans,Philippe Moris,Marcelle Van Mechelen,Michèle Janssens,Marguerite Koutsoukos,Pascale Van Belle,Frédéric Clement,Emmanuel Hanon,Martine Wettendorff,Nathalie Garçon,Geert Leroux-Roels +11 more
TL;DR: The Adjuvant Systems containing MPL/QS21, in combination with hepatitis B surface antigen, induced very strong humoral and cellular immune responses in healthy adults and can be fundamental to develop effective prophylactic vaccines against complex pathogens, e.g. malaria, HIV infection and tuberculosis.
Journal ArticleDOI
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans.
Kenneth Von Eschen,Royce Morrison,Madeleine Braun,Opokua Ofori-Anyinam,Els De Kock,Priya Pavithran,Marguerite Koutsoukos,Philippe Moris,Daniel Cain,Marie-Claude Dubois,Joe Cohen,W. Ripley Ballou +11 more
TL;DR: This first trial in humans found Mtb72F/AS02A to have an, acceptable tolerability, to be immunogenic in healthy adults and warrants further development of the vaccine.
Journal ArticleDOI
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
Glenda Gray,Glenda Gray,Glenda Gray,Linda-Gail Bekker,Fatima Laher,Mookho Malahleha,Mary Allen,Zoe Moodie,Nicole Grunenberg,Yunda Huang,Doug Grove,Brittany Prigmore,Jia J. Kee,David Benkeser,John Hural,Craig Innes,Erica Lazarus,Graeme Meintjes,Nivashnee Naicker,Dishiki Jenny Kalonji,Maphoshane Nchabeleng,Modulakgotla Sebe,Nishanta Singh,Philip Kotze,Sheetal Kassim,Thozama Dubula,Vimla Naicker,William Brumskine,Cleon N. Ncayiya,Amy Ward,Nigel Garrett,Girisha Kistnasami,Zakir Gaffoor,Pearl Selepe,Philisiwe B. Makhoba,Matsontso Mathebula,Pamela Mda,Tania Adonis,Katlego S. Mapetla,Bontle Modibedi,Tricia Philip,Gladys Kobane,Carter Bentley,Shelly Ramirez,Simbarashe Takuva,Megan Jones,Mpho Sikhosana,Millicent Atujuna,Michele P. Andrasik,Nima S. Hejazi,Adrian Puren,Lubbe Wiesner,Sanjay Phogat,Sanjay Phogat,Carlos Diaz Granados,Marguerite Koutsoukos,Olivier Van Der Meeren,Susan W. Barnett,Niranjan Kanesa-thasan,James G. Kublin,M. Juliana McElrath,Peter B. Gilbert,Holly Janes,Lawrence Corey +63 more
TL;DR: In this article, a canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand.